Abstract 【Objective】To investigate the efficacy of bevacizumab combined with paclitaxel+cisplatin (TP) based synchronous radiochemotherapy in the treatment of cervical cancer. 【Methods】Ninety cervical cancer patients admitted to our hospital from December 2021 to January 2023 were selected and randomly divided into the observation group and the control group using a random number table method, with 45 patients in each group. The control group was treated with TP synchronous radiotherapy and chemotherapy, while the observation group was treated with bevacizumab on the basis of the control group. One treatment cycle was 21 days, and both groups were treated for three cycles. Two groups were compared in terms of clinical efficacy, serological indicators, immune function indicators, quality of life scores, and incidence of adverse reactions. 【Results】The clinical remission rate of the observation group (55.56%) was higher than that of the control group (33.33%) (P<0.05). After treatment, the levels of serum carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen (SCC), and transforming growth factor beta 1 (TGF-β1) decreased in both groups (P<0.05), and the above indicators in the observation group were lower than those in the control group (P<0.05). After treatment, the observation group had higher levels of CD3+ and CD4+ than the control group (P<0.05), and lower levels of CD8+ than the control group (P<0.05). After treatment, the FACT-G scores of both groups of cancer treatment function evaluation scales increased (P<0.05), and the FACT-G score of the observation group was higher than that of the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 The combination of bevacizumab and TP based synchronous chemoradiotherapy is effective in treating cervical cancer patients, improving their immune function and quality of life, reducing tumor markers and TGF-β1 expression levels, and has good safety. It is worthy of clinical application.
[1] KOSKAS M, AMANT F, MIRZA M R, et al. Cancer of the corpus uteri: 2021 update[J].Int J Gynaecol Obstet,2021,155 (1):45-60.
[2] 洪文翠,吕银. 局部晚期子宫颈癌放化疗后复发危险因素分析及列线图预测模型的构建[J].实用妇产科杂志,2023,39(4):302-307.
[3] 汤小龙,陈旭峰,郑杨,等. 贝伐珠单抗联合顺铂腹腔给药治疗胃癌腹水的效果[J].中国医药导报,2021,18(23):88-91.
[4] 梁丹,张又红,苏天海,等. 分次立体定向放疗同步化疗联合贝伐珠单抗治疗肺癌脑转移的疗效及安全性[J].中南药学,2023,21(3):823-827.
[5] 中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):474-489.
[6] SCHWARTZ L H, SEYMOUR L, LITIERE S, et al. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group[J].Eur J Cancer,2016,62(3):138-145.
[7] 李道娟,师金,靳晶,等. 宫颈癌的流行病学趋势[J].中华肿瘤杂志,2021,43(9):912-916.
[8] 孔为民,陈姝宁. 规范妇科恶性肿瘤诊疗,关注临床新进展[J].中国临床医生杂志,2023,51(3):253-257.
[9] PRSA G, SERDINSEK T. Management of concomitant pelvic floor disorders and gynecological malignancy: a clinical challenge[J].Int Urogynecol J,2022,33(3):451-452.
[10] 唐梦君,杨昕,丁叔波. MRI指导的骨髓保护调强放疗在宫颈癌术后同步放化疗中的应用研究[J].重庆医学,2023,52(5):742-746.
[11] CHEN W J, XIU S Y, XIE X Y, et al. Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer[J].Radiat Oncol,2022,17(1):6.
[12] 杨雪,孟凡路,钟殿胜. 阿美替尼联合贝伐珠单抗治疗晚期NSCLC伴原发EGFR T790M突变:3例病案报道及文献复习[J].中国肺癌杂志,2023,26(2):158-164.
[13] 邹亚,钟萍,罗楠,等. 贝伐珠单抗联合多西他赛及吉西他滨治疗复发性铂类耐药晚期卵巢癌临床效果及随访1年预后[J].中国计划生育学杂志,2023,31(3):547-551.
[14] 李金燕,吕伯乐,吕姗,等. 贝伐珠单抗联合化疗对晚期肺癌患者血清肿瘤标志物及免疫功能的影响[J].癌症进展,2021,19(18):1896-1899.
2024, Vol. 41 
